IBDEI2TR ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45054,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,45055,0)
 ;;=L27.0^^170^2245^37
 ;;^UTILITY(U,$J,358.3,45055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45055,1,3,0)
 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,45055,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,45055,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,45056,0)
 ;;=L27.1^^170^2245^38
 ;;^UTILITY(U,$J,358.3,45056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45056,1,3,0)
 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,45056,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,45056,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,45057,0)
 ;;=L51.1^^170^2245^44
 ;;^UTILITY(U,$J,358.3,45057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45057,1,3,0)
 ;;=3^Stevens-Johnson Syndrome
 ;;^UTILITY(U,$J,358.3,45057,1,4,0)
 ;;=4^L51.1
 ;;^UTILITY(U,$J,358.3,45057,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,45058,0)
 ;;=L51.3^^170^2245^45
 ;;^UTILITY(U,$J,358.3,45058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45058,1,3,0)
 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
 ;;^UTILITY(U,$J,358.3,45058,1,4,0)
 ;;=4^L51.3
 ;;^UTILITY(U,$J,358.3,45058,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,45059,0)
 ;;=Z12.83^^170^2245^21
 ;;^UTILITY(U,$J,358.3,45059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45059,1,3,0)
 ;;=3^Screening for Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,45059,1,4,0)
 ;;=4^Z12.83
 ;;^UTILITY(U,$J,358.3,45059,2)
 ;;=^5062696
 ;;^UTILITY(U,$J,358.3,45060,0)
 ;;=Z48.817^^170^2245^48
 ;;^UTILITY(U,$J,358.3,45060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45060,1,3,0)
 ;;=3^Surgical Aftercare Following Skin Surgery
 ;;^UTILITY(U,$J,358.3,45060,1,4,0)
 ;;=4^Z48.817
 ;;^UTILITY(U,$J,358.3,45060,2)
 ;;=^5063054
 ;;^UTILITY(U,$J,358.3,45061,0)
 ;;=L94.0^^170^2245^20
 ;;^UTILITY(U,$J,358.3,45061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45061,1,3,0)
 ;;=3^Scleroderma,Localized
 ;;^UTILITY(U,$J,358.3,45061,1,4,0)
 ;;=4^L94.0
 ;;^UTILITY(U,$J,358.3,45061,2)
 ;;=^5009470
 ;;^UTILITY(U,$J,358.3,45062,0)
 ;;=D23.9^^170^2245^22
 ;;^UTILITY(U,$J,358.3,45062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45062,1,3,0)
 ;;=3^Sebaceous Hyperplasia
 ;;^UTILITY(U,$J,358.3,45062,1,4,0)
 ;;=4^D23.9
 ;;^UTILITY(U,$J,358.3,45062,2)
 ;;=^5002076
 ;;^UTILITY(U,$J,358.3,45063,0)
 ;;=L21.9^^170^2245^23
 ;;^UTILITY(U,$J,358.3,45063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45063,1,3,0)
 ;;=3^Seborrhea,Unspec
 ;;^UTILITY(U,$J,358.3,45063,1,4,0)
 ;;=4^L21.9
 ;;^UTILITY(U,$J,358.3,45063,2)
 ;;=^188703
 ;;^UTILITY(U,$J,358.3,45064,0)
 ;;=L91.8^^170^2245^39
 ;;^UTILITY(U,$J,358.3,45064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45064,1,3,0)
 ;;=3^Skin Tag
 ;;^UTILITY(U,$J,358.3,45064,1,4,0)
 ;;=4^L91.8
 ;;^UTILITY(U,$J,358.3,45064,2)
 ;;=^5009460
 ;;^UTILITY(U,$J,358.3,45065,0)
 ;;=I83.12^^170^2245^43
 ;;^UTILITY(U,$J,358.3,45065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45065,1,3,0)
 ;;=3^Stasis Dermatitis.Left Leg
 ;;^UTILITY(U,$J,358.3,45065,1,4,0)
 ;;=4^I83.12
 ;;^UTILITY(U,$J,358.3,45065,2)
 ;;=^5007989
 ;;^UTILITY(U,$J,358.3,45066,0)
 ;;=I83.11^^170^2245^42
 ;;^UTILITY(U,$J,358.3,45066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45066,1,3,0)
 ;;=3^Stasis Dermatitis,Right Leg
 ;;^UTILITY(U,$J,358.3,45066,1,4,0)
 ;;=4^I83.11
 ;;^UTILITY(U,$J,358.3,45066,2)
 ;;=^5007988
 ;;^UTILITY(U,$J,358.3,45067,0)
 ;;=C84.19^^170^2245^26
